Navigation Links
CV Therapeutics Announces Presentations at the American Diabetes Association 68th Scientific Sessions
Date:5/27/2008

PALO ALTO, Calif., May 27 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that two clinical abstracts have been accepted for presentation at the American Diabetes Association (ADA) 68th Scientific Sessions, which will be held in San Francisco, CA on June 6 - 10, 2008.

Ranexa(R) (ranolazine extended-release tablets)

Relationship Between Nonfasting Plasma Glucose Concentrations and Improved Glycemic Control in Patients with Diabetes and Coronary Artery Disease Treated with Ranolazine; Poster; Sunday, June 8, 2008, 12:00 - 2:00 p.m. and 6:15 - 7:30 p.m. PDT

Minority Angina Pectoris Patients at High Risk for Diabetes and Metabolic Syndrome; Poster; Sunday, June 8, 2008, 12:00 - 2:00 p.m. and 6:15 - 7:30 p.m. PDT

Additional information regarding the ADA 68th Scientific Sessions can be accessed at http://professional.diabetes.org/Congress_Display.aspx?TYP=9&CID=58000.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved products include Ranexa(R) (ranolazine extended-release tablets), indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and Lexiscan(TM) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. CV Therapeuti
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 31, 2014 Huge event with ... future pharma industry health, analysis and forecasting   ... the closing of its most successful show to date ... 2,500 exhibitors. Held this year in Paris ... key players from 140+ countries representing every step of ...
(Date:10/31/2014)... Jeffrey T. Manuel, assistant professor in Southern ... College of Arts and Sciences, is teaming up with ... alcohol-based fuels in Illinois. , “Farmers, researchers, ... to build Illinois’ biofuels industry for decades,” Manuel said. ... state's agricultural and business history. , “Fuel alcohol ...
(Date:10/31/2014)... ENVIRON , an international ... that Dr. Harvey Clewell III has rejoined the ... closely with senior professionals in ENVIRON’s Health Sciences ... at The Hamner Institutes for Health Sciences (The ... he is Director, Center for Human Health Assessment. ...
(Date:10/30/2014)... -- Investor-Edge has initiated coverage on the ... Inc. (NASDAQ: MDVN ), Pharmacyclics Inc. (NASDAQ: ... SYN), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). Free research ... http://investor-edge.com/register . On Wednesday, October 29, 2014, ... Dow Jones Industrial Average declined 0.18%, to finish the ...
Breaking Biology Technology:CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 2CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 3CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 4CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 5CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 6SIUE History Prof Manuel Working on Biofuels Book with NCERC 2SIUE History Prof Manuel Working on Biofuels Book with NCERC 3Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5
... March 16, Shire plc (LSE: SHP, NASDAQ: ... the U.S. District Court of the Southern District of,New ... three,of Shire,s patents: U.S. Patent No. 5,968,976 (",976 Patent"); ... (",465"). , The lawsuit was ...
... AutoImmune Inc. (OTC Bulletin Board: AIMM) today reported a net ... for the three months ended December 31, 2008, compared with ... basic and diluted, for the three months ended December 31, ... loss was $345,000, or $0.02 per share basic and diluted, ...
... 16 Contamination by mycoplasmal organisms is an ... them ready sources of contamination, while rendering them ... white paper, examines how PCR mycoplasma tests ... minimizes testing delays and enable safe, high-volume biopharmaceutical ...
Cached Biology Technology:Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents 2AutoImmune Inc. Reports 2008 Fourth Quarter and Year End Financial Results 2AutoImmune Inc. Reports 2008 Fourth Quarter and Year End Financial Results 3AutoImmune Inc. Reports 2008 Fourth Quarter and Year End Financial Results 4New White Paper Examines Advanced Mycoplasma Tests - How Real-Time PCR Analysis Helps Save Time and Money for Biopharmaceutical Manufacturers 2New White Paper Examines Advanced Mycoplasma Tests - How Real-Time PCR Analysis Helps Save Time and Money for Biopharmaceutical Manufacturers 3
(Date:10/29/2014)... At a ceremony held in New York City on ... King, the American Cancer Society Professor of Genome Sciences ... and 2008 Honorary Doctor of Philosophy of Tel Aviv ... in Medical Science. , In addition to her honorary ... Lecturer at the TAU School of Medicine, and for ...
(Date:10/29/2014)... One kind of stem cell, those referred to as ... There is apparently nothing that differentiates these cells from ... namely they retain the capacity to become stem cells ... liver, an organ that hosts cells that stimulate tissue ... the case of a transplant. Knowledge of the ...
(Date:10/29/2014)... in the living world compete with members of ... how much they invest into their competitive ability. ... get access to high-quality resources, while others seem ... the lower-quality resources that are left over for ... and human societies seems to fluctuate considerably over ...
Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2A mechanism that allows a differentiated cell to reactivate as a stem cell revealed 2Evolution of competitiveness 2Evolution of competitiveness 3
... HOUSTON (Dec. 5, 2013) A new method ... proteins may speed the process of novel drug design, ... combination of computational techniques and experimental data helped Rice ... have been hard to detect. The work ...
... CHAMPAIGN, Ill. A 115-million-year-old fossilized wasp from northeast Brazil ... organ through which it lays its eggs, looks a lot ... figs. The problem, researchers say, is that figs arose about ... report of the findings appears in the journal ...
... levers: miniaturized robots of the future will be "soft". , ... to mind are the tentacles of an octopus or the ... a crane or the inner workings of a watch. And ... organisms moving in water. The robots of the future will ...
Cached Biology News:Proteins' passing phases revealed 2Proteins' passing phases revealed 3Ancient 'fig wasp' lived tens of millions of years before figs 2'Soft' (and miniaturized) robots 2
... the ideal CO2 incubator for cell and ... embryos at or near body temperature. HERAcell ... needed to protect and grow your valuable ... incubation conditions ensure optimum culture growth. ...
SP6 RNA Polymerase, 50 l, 20 U/l ,Cap Scribe Buffer, 100 l, 5x conc....
...
... High Vacuum pumps deliver critical performance ... gas ballast control optimizes pump performance to ... glass allows for convenient checking of proper ... series of pumps is designed to work ...
Biology Products: